Medicare Initiative Set to Lower Cost of Popular Weight-Loss Medications

Millions of Medicare recipients may soon benefit from reduced costs on popular weight-loss drugs. Some could pay just $50 a month under a new federal initiative, the Medicare GLP-1 Bridge program, launching on July 1. This program aims to make high-demand medications more accessible to seniors.

Significance of the Initiative

The program represents a major shift in Medicare drug access. Historically, Medicare could not cover weight-loss medications. However, GLP-1 drugs have become popular due to their effectiveness in promoting weight loss and lowering the risk of chronic conditions such as heart disease.

Despite these benefits, the high cost of GLP-1 medications, which can exceed $900 monthly without insurance, limits access. By capping costs at $50 a month, the program could enable millions of seniors to access treatment.

Program Details

Starting July 1, eligible Medicare beneficiaries with drug coverage can access specific GLP-1 medications for a flat monthly cost of $50. The Centers for Medicare & Medicaid Services (CMS) will oversee the temporary program, which runs until December 31, 2027.

“These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost,” CMS Administrator Dr. Mehmet Oz stated. “The Medicare GLP-1 Bridge changes that, making these medications more affordable and accessible.”

GLP-1 drugs, such as Wegovy, Foundayo, and Zepbound, initially treated Type 2 diabetes but are now prescribed for weight loss and related conditions.

Eligibility Criteria

To qualify, recipients must:

• Be enrolled in a Medicare Part D or Medicare Advantage drug plan
• Have a doctor’s prescription and prior authorization
• Meet medical criteria, like obesity or specific related conditions

Patients should work with healthcare providers to submit necessary documentation through CMS’s centralized system.

Medications and Pricing

The Medicare GLP-1 Bridge program provides Part D plan members access to some medications, including:

• Foundayo
• Wegovy (injection or tablet)
• Zepbound (KwikPen)

The program functions outside standard Part D coverage rules. The $50 fee is a flat copay for a 30-day supply, not counting toward deductibles or annual out-of-pocket limits.

“This bridge program will now allow Medicare beneficiaries access to GLP-1 medications for weight loss through a monthly subscription model,” said Kevin Thompson, CEO of 9i Capital Group. “Questions remain about its sustainability.”

Steps for Medicare Beneficiaries

If you are on Medicare, consider these steps:

• Check eligibility: Consult your doctor to determine if you qualify.
• Confirm drug coverage: Ensure your GLP-1 medication is included.
• Prepare for July 1: The program launches nationwide on this date.

Future Considerations

The GLP-1 Bridge is a temporary measure to inform future CMS policy decisions. The long-term outlook is uncertain. Without an extension past 2027, patient access may end, possibly reversing health improvements during the program period.

“The greatest concern is that while in the short-term the program could provide health benefits, in the long-term similar problems could return if the program is not extended,” stated Alex Beene, a financial literacy instructor.

For further inquiries about this story, contact Newsweek editors Jason Lemon and Anthony Murray.